Mandatory Research Biopsy Requirements Delay Initiation of Clinical Trials by Jonathan H. Cheng, Justin W. Tiulim, Sheng Zhou, Anthony El-Khoueiry, Jorge Nieva

Get full text

Etiology and Outcomes of Hepatocellular Carcinoma in an Ethnically Diverse Population: The Multiethnic Cohort by Afsaneh Barzi, Kali Zhou, Songren Wang, Jennifer L. Dodge, Anthony El-Khoueiry, Veronica Wendy Setiawan

Get full text

411 Novel intratumoral agent, INT230–6 induces cancer cell death, increases tumor infiltrates and results in durable benefit alone or in combination with pembrolizumab in refractor... by Lilian Siu, Jacob Thomas, Diana Hanna, Anthony El-Khoueiry, Nilofer Azad, Lewis Bender, Ian Walters, Giles Whalen, Matthew Ingham

743 INCLINE-101: preliminary safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TAC-001 (TLR9 agonist conjugated to a CD22 mAb) in patients with advanced or... by Joshua Lee, Anna Pavlick, Feng Jin, Cesar Perez, Martin Gutierrez, Anthony El-Khoueiry, Ons Harrabi, Jason Henry, Sunnie Kim, Sangeetha Bollini, Kevin N Heller, Timothy Humphries

479 AGEN1181, an Fc-enhanced anti-CTLA-4 antibody, alone and in combination with balstilimab (anti-PD-1) in patients with advanced solid tumors: Initial phase I results by Andrea Bullock, Justin Moser, Daruka Mahadevan, Michael Gordon, Przemyslaw Twardowski, Apostolia Tsimberidou, Breelyn Wilky, Waldo Ortuzar Feliu, Anthony El-Khoueiry, Steven O’Day, Bruno Bockorny, Katherine Rosenthal

771 A phase 1 study to assess safety, efficacy, pharmacokinetics, and pharmacodynamics of intratumoral CLN-617 (IL2/IL12 fusion protein) combined with pembrolizumab in patients wit... by Evan Hall, Adi Diab, Sajeve Thomas, Randy Sweis, Anthony El-Khoueiry, Naveen K Mehta, Jennifer S Michaelson, Laura Liu, Reham Abdel-Wahab, Jeffrey A Jones, Kaida Wu, Benjamin S Maciejewski

Profiling of Circulating Tumor Cells for Screening of Selective Inhibitors of Tumor‐Initiating Stem‐Like Cells by Chia‐Lin Chen, Juan Carlos Hernandez, Dinesh Babu Uthaya Kumar, Tatsuya Machida, Stanley M. Tahara, Anthony El‐Khoueiry, Meng Li, Vasu Punj, Suresh Kumar Swaminathan, Ameya Kirtane, Yibu Chen, Jayanth Panyam, Keigo Machida

Get full text

735 Peripheral and tissue persistence of agenT-797, an allogeneic iNKT cell-based cell therapy for the treatment of cancer by Rachel E Sanborn, Trisha M Wise-Draper, Marc Van Dijk, Breelyn Wilky, Anthony El-Khoueiry, John Hamm, Benjamin Garmezy, Benedito Carneiro, Jamie Moon, Sue Ryu, Irene R Ramos, Marco A Purbhoo, Dave SB Hoon

Comparative Efficacy of Atezolizumab plus Bevacizumab and Other Treatment Options for Patients with Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis by Arndt Vogel, Lorenza Rimassa, Hui-Chan Sun, Ghassan K. Abou-Alfa, Anthony El-Khoueiry, David J. Pinato, Javier Sanchez Alvarez, Monica Daigl, Panos Orfanos, Michael Leibfried, Marie-Hélène Blanchet Zumofen, Vincent E. Gaillard, Philippe Merle

Get full text

651 A phase 1, multicenter, open-label, dose-escalation, safety, pharmacodynamic, pharmacokinetic study of Q702 with a cohort expansion at the RP2D in patients with advanced solid... by Angela Alistar, Alain Mita, Devalingam Mahalingam, Anthony El-Khoueiry, Jeongjun Kim, Hyunji Ahn, Jinho Choi, Seung-Hee Ryu, Jiye Ahn, Bae Jung Choi, Hwankyu Kang, Yeong-In Yang, Seung-Joo Lee, Borami Jeon, Stefan Proniuk, Kiyean Nam

759 ADPORT-601 (TT-10–101): first-in-human study of adenosine 2A (A2A) and adenosine 2B (A2B) receptor antagonists in participants with selected advanced solid tumors by Lawrence Fong, Sumit Subudhi, Gerald S Falchook, Russell Pachynski, Anthony El-Khoueiry, Ian Walters, Robert Krämer, Sushant Kumar, Kasim Mookhtiar, Justin Fairchild, Mohamad A Salkeni, Jaspreet Grewal, William Tester, Samik Upadhaya, Ana Rosa Saez Ibanez, Desa Rae Stanton-Pastore

611 XTX202–01/02–001, Phase 1/2 first-in human study of XTX202, a masked, tumor-activated IL-2βγ, in patients with advanced solid tumors: results from phase 1 by David Miller, John Powderly, Suthee Rapisuwon, Sanjay Goel, Bartosz Chmielowski, Richard Wu, Meredith McKean, Damiano Fantini, Yousef Zakharia, Jacob Thomas, Diana Hanna, Anthony El-Khoueiry, Ekta Patel, Anurag Gupta, George Lee, Meghan Duncan, Meredith Pelster, Randy Hurley, Aika Siu, David Crowe, Sattanathan Paramasivan, Katarina Luptakova

645 A phase 1B/2, open-label study of Q702 in combination with intravenous pembrolizumab in patients with selected advanced solid tumors by Do-Youn Oh, Seung-Tae Kim, Sun Young Rha, Anthony El-Khoueiry, Hong Jae Chon, Jaspreet Grewal, Jeongjun Kim, Hyunji Ahn, Jinho Choi, Seung-Hee Ryu, Jiye Ahn, Bae Jung Choi, Hwankyu Kang, Yeong-In Yang, Seung-Joo Lee, Borami Jeon, Stefan Proniuk, Kiyean Nam, Baek-Yeol Ryoo

1043 Intratumoral mRNA IL-12 can induce a dose dependent immunostimulatory effect within tumor microenvironment in patients with advanced solid tumors by Vivek Subbiah, Dmitriy Zamarin, Omid Hamid, Igor Feldman, Thomas Marron, Yuling Wu, Inderjit Mehmi, Michael Abadier, Analia Azaro, Anthony El-Khoueiry, Eduardo Castañón Álvarez, Jacky Chow, Praveen Aanur, Khanh Do, Vasudha Sehgal, Sandip P Patel, Benedito Carneiro, Linh Van, Nicholas Durham, Xiaoru Chen, Paula G Fraenkel, Arjun Oberoi